Black J, Reaven N L, Funk S E, McGaughey K, Ohayon M M, Guilleminault C, Ruoff C
Stanford University, Palo Alto, CA, USA; Jazz Pharmaceuticals, Palo Alto, CA, USA.
Strategic Health Resources, La Canada, CA, USA.
Sleep Med. 2017 May;33:13-18. doi: 10.1016/j.sleep.2016.04.004. Epub 2016 May 12.
OBJECTIVE/BACKGROUND: The objective of this study was to evaluate medical comorbidity patterns in patients with a narcolepsy diagnosis in the United States.
PATIENTS/METHODS: This was a retrospective medical claims data analysis. Truven Health Analytics MarketScan® Research Databases were accessed to identify individuals ≥18 years of age with ≥1 diagnosis code for narcolepsy (International Classification of Diseases (ICD)-9, 347.0, 347.00, 347.01, 347.1, 347.10, or 347.11) continuously insured between 2006 and 2010, and controls without narcolepsy matched 5:1 on age, gender, region, and payer. Narcolepsy and control subjects were compared for frequency of comorbid conditions, identified by the appearance of >1 diagnosis code(s) mapped to a Clinical Classification System (CCS) level 1 category any time during the study period, and on specific subcategories, including recognized narcolepsy comorbidities of obstructive sleep apnea (OSA) and depression.
The final study group included 9312 subjects with narcolepsy and 46,559 controls (each group: average age, 46.1 years; 59% female). As compared with controls, patients with narcolepsy showed a statistically significant excess prevalence in all the CCS multilevel categories, the only exceptions being conditions originating in the perinatal period and pregnancy/childbirth complications. The greatest excess prevalence in the narcolepsy cohort was seen for mental illness (31.1% excess prevalence; odds ratio (OR) 3.8, 95% confidence interval (CI) 3.6, 4.0), followed by diseases of the digestive system (21.4% excess prevalence; OR 2.7, 95% CI 2.5, 2.8) and nervous system/sense organs (excluding narcolepsy; 20.7% excess prevalence; OR 3.7, 95% CI 3.4, 3.9).
In this claims analysis, a narcolepsy diagnosis was associated with a wide range of comorbid medical illness claims, at significantly higher rates than matched controls.
目的/背景:本研究的目的是评估美国发作性睡病患者的合并症模式。
患者/方法:这是一项回顾性医疗索赔数据分析。访问了Truven Health Analytics MarketScan®研究数据库,以识别年龄≥18岁、在2006年至2010年期间连续参保且有≥1个发作性睡病诊断代码(国际疾病分类(ICD)-9,347.0、347.00、347.01、347.1、347.10或347.11)的个体,以及在年龄、性别、地区和付款人方面按5:1匹配的无发作性睡病对照。比较发作性睡病患者和对照受试者合并症的发生频率,合并症通过在研究期间任何时间出现>1个映射到临床分类系统(CCS)1级类别的诊断代码来确定,并比较特定子类别,包括公认的发作性睡病合并症阻塞性睡眠呼吸暂停(OSA)和抑郁症。
最终研究组包括9312名发作性睡病患者和46559名对照(每组:平均年龄46.1岁;59%为女性)。与对照相比,发作性睡病患者在所有CCS多级类别中的患病率均有统计学意义的显著增加,唯一的例外是围生期起源的疾病和妊娠/分娩并发症。发作性睡病队列中患病率增加最多的是精神疾病(患病率增加31.1%;优势比(OR)3.8,95%置信区间(CI)3.6,4.0),其次是消化系统疾病(患病率增加21.4%;OR 2.7,95%CI 2.5,2.8)和神经系统/感觉器官(不包括发作性睡病;患病率增加20.7%;OR 3.7,95%CI 3.4,3.9)。
在这项索赔分析中,发作性睡病诊断与多种合并症医疗索赔相关,其发生率显著高于匹配的对照。